Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.7199
+0.0324 (4.71%)
At close: Apr 23, 2025, 4:00 PM
0.7150
-0.0049 (-0.68%)
After-hours: Apr 23, 2025, 5:01 PM EDT
Ocugen Employees
Ocugen had 95 employees as of December 31, 2024. The number of employees increased by 30 or 46.15% compared to the previous year.
Employees
95
Change (1Y)
30
Growth (1Y)
46.15%
Revenue / Employee
$42,684
Profits / Employee
-$568,989
Market Cap
209.37M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
OCGN News
- 15 days ago - Ocugen to Present at the 2025 Cell & Gene Meeting on the Med - GlobeNewsWire
- 5 weeks ago - Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema - GlobeNewsWire
- 7 weeks ago - Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease - GlobeNewsWire
- 2 months ago - Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 2 months ago - Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa - GlobeNewsWire